The first once-weekly basal insulin approved in the United States is now stocked at more than 70,000 pharmacies, and the most important thing for a patient starting it is not the convenience. It is the concentration.
Insulin Icodec-Abae, sold as Awiqli, is formulated at 700 units/mL. Standard long-acting insulins such as glargine are U-100. That is a sevenfold difference in strength sitting in the same refrigerator, in a pen that looks broadly similar to the ones a household may already have.
The product genuinely reduces basal injections from seven a week to one, and for people who struggle with daily injections, that matters. But the prescribing information carries warnings that apply to no other basal insulin on the US market, and those warnings are worth a careful conversation before the first dose.
A U-700 Pen Sits Next to U-100 Pens in the Same Refrigerator
The prescribing information includes explicit instructions that read as unusual because they are. As detailed in clinical coverage of the approval, the label warns against using a syringe to withdraw insulin from the pen, against dialing the maximum single dose of 700 units unless it has been specifically prescribed, and against mixing or diluting the product with any other insulin.
Each of those warnings exists because the failure mode is severe. Drawing U-700 insulin into a syringe marked for U-100 would deliver seven times the intended dose. European regulators anticipated this. When the product was authorized there, the European Medicines Agency required educational materials for both clinicians and patients specifically to prevent confusion with other insulin pens, warning that dosing errors "could result in patients receiving too much or too little insulin," with possible consequences including loss of consciousness, coma, or death.
There is a second layer to the risk of confusion. Patients switching from a daily long-acting insulin may be prescribed a higher one-time first dose, a deliberate part of the regimen rather than an error, meaning the first week's dose can differ from subsequent weeks. EMA guidance is explicit that this higher dose is for the first injection only.
The guardrails are ordinary. Use only the pen the product comes in. Inject on the same calendar day each week. Store it apart from any daily pen. Anyone who helps administer the injection, including a family caregiver or home health aide, needs to know this is a weekly product at an unfamiliar strength.
Type 1 Diabetes Was Left Out for a Documented Reason
The approval covers adults with type 2 diabetes only. It does not cover type 1 diabetes, and it is not indicated for children. That boundary is not an oversight or a paperwork gap, and its history is public.
The company originally sought approval for both major types of diabetes. In May 2024, an FDA advisory committee voted 7 to 4 against concluding that the benefits outweighed the risks in type 1 diabetes, driven by hypoglycemia concerns. The committee did not evaluate use in type 2 diabetes. The FDA issued a complete response letter in July 2024 citing manufacturing questions and the type 1 indication, and the company subsequently refocused the application, as reported by Medscape.
That history is useful context for a patient with type 1 diabetes who reads a headline about weekly insulin. The product is not available to them in the United States; additional type 1 studies are ongoing, and asking a clinician to prescribe it off-label would run against the specific safety concern regulators identified.
The efficacy case in type 2 diabetes rests on the ONWARDS program, four randomized treat-to-target trials in approximately 2,680 adults with uncontrolled type 2 diabetes, comparing weekly icodec with daily basal insulin alongside mealtime insulin, oral agents or GLP-1 receptor agonists. The trials met the primary endpoint of noninferiority for HbA1c reduction. Noninferiority means blood sugar control was shown not to be meaningfully worse than better, which is the honest reading.
A Weekly Dose Cannot Be Pulled Back Once It Is Given
The structural trade-off of a weekly insulin is that the dose is committed. With a daily basal insulin, a patient anticipating an unusually active day, an illness, or a skipped meal can adjust the next day's dose. With a weekly product, the insulin is already circulating, and titration happens in larger increments on a weekly rather than daily rhythm.
The flexibility runs the other way for missed doses. A patient who forgets the scheduled day can take the dose within four days and then resume the weekly cadence, which is a meaningful difference from a missed daily injection.
Reported adverse events align with the basal insulin class and include hypoglycemia, injection site reactions, skin thickening or pitting at the injection site, itching, rash, swelling of the hands and feet, and weight gain. Serious allergic reactions have been described with insulin products generally.
Julio Rosenstock, a principal investigator in the ONWARDS program, said in the Novo Nordisk announcement that a weekly option "may reshape insulin management in adults with type 2 diabetes." Not everyone expects broad uptake. Kasia Lipska, a Yale School of Medicine endocrinologist, told The New York Times she expects it to remain a niche product, arguing that its long duration of action is simultaneously its main advantage and its central limitation, particularly for older patients in whom hypoglycemia is harder to manage.
The population that may benefit most includes people who miss doses and people who depend on a caregiver to administer injections. Anyone starting this product should keep fast-acting carbohydrates available and, where prescribed, glucagon. Symptoms of low blood sugar, including shakiness, sweating, confusion, rapid heartbeat, and blurred vision, warrant immediate treatment with fast-acting sugar, and severe hypoglycemia with loss of consciousness or seizure is an emergency requiring 911.
Cost is less of a barrier than usual. The company cites a list price of $99 per package, with $35 monthly for eligible patients with commercial insurance or Medicare and $55 for uninsured patients, according to Managed Healthcare Executive. Savings card terms exclude patients whose plans use copay accumulator or maximizer arrangements. Formulary placement is decided plan by plan, so confirm coverage rather than assume it.
A post-marketing safety study is underway in Japan, and additional trials in type 1 diabetes are ongoing. Reporting by Healio noted the trial safety profile was similar to that of daily basal insulins. MedicalDaily will report new safety data and any label changes.
Key Questions Answered
What does U-700 mean, and why does it matter? It means 700 units of insulin per milliliter, seven times the concentration of standard U-100 insulin. A dosing error involving the wrong device or measurement could deliver a very large overdose.
Can this insulin be drawn into a syringe? No. The prescribing information explicitly warns against withdrawing insulin from the pen with a syringe. It should be given only with the pen it comes in.
Is it approved for type 1 diabetes? Not in the United States. The US approval covers adults with type 2 diabetes only. An FDA advisory committee voted against a favorable benefit-risk conclusion in type 1 diabetes over hypoglycemia concerns, and further type 1 studies are ongoing.
Is it approved for children? No. The indication is for adults, and safety and effectiveness in children have not been established.
Does it control blood sugar better than daily insulin? The trials met the noninferiority standard for HbA1c reduction compared with daily basal comparators. Noninferiority means not meaningfully worse, which is the more conservative and more common finding.
What happens if a dose is missed or the week does not go as planned? A missed dose can be taken within four days before resuming the weekly schedule. The dose already given cannot be reduced mid-week, so anyone planning increased activity should discuss monitoring in advance.
What should a caregiver know? That it is a weekly product at an unfamiliar concentration, which calendar day the dose is due, that the pen is not interchangeable with daily insulin pens, and how to recognize and treat low blood sugar.
